PBXIP1 and neoplasm: At variance with the previously quoted tumor-inducing role in this type of cancer (He et al., 2017; Liu et al., 2021), other authors reported overexpression of the PBX1 inhibitor PBXIP1 in gastric cancer patients, leading to repressed PBX1 transcriptional activity and promotion of cell proliferation, migration, and invasion (Feng et al., 2015).